|
|
|
| Cardioprotective effect of dexrazoxane in patients with type 2 diabetes accompanying gastric cancer treated with epirubicin chemotherapy |
| JIANG Jing 1, WEI Hui 1, HOU Jun-ming 2, XIAO Gang 3 |
| (1. Department of Tumor; 2. Department of Oncological Surgery; 3. Department of General Surgery, the Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang Shaanxi 712046， China) |
|
|
|
|
Abstract Objective: To investigate the myocardium protective effect of dexrazoxane in patients with type 2 diabetes accompanying gastric cancer treated with epirubicin chemotherapy. Methods: Eighty cases of patients with type 2 diabetes accompanying gastric cancer were treated and divided into two groups randomly.The control group was treated with epirubicin combination chemotherapy,the observation group was treated with epirubicin combination chemotherapy and dexrazoxane.The levels of troponin I and B type natriuretic peptide in two groups before and after treatment were compared, and the incidence of abnormal ECG in the two groups was compared. Results: There was no significant difference in the levels of troponin I and B type natriuretic peptide in the two groups before treatment(P>0.05); after treatment and follow-up period, the troponin I and B type natriuretic peptide in the observation group were significantly lower than those in the control group(P<0.05); after treatment, the abnormal rate of ECG in the observation group was 27.50%(11/40), which was significantly lower than that in the control group 52.50%(21/40) (P<0.05); by following up for 6 months, the abnormal rate of ECG in the observation group was 17.50%(7/40), which was significantly lower than 37.50%(15/40) of the control group(P<0.05). Conclusion: Dexrazoxane was shown to have effective cardiac protective function in patients with type 2 diabetes accompanying gastric cancer treated with epirubicin chemotherapy, it can also treat the existing heart damage, so that the clinical application of epirubicin is promising. ［Key words］dexrazoxane; epirubicin; type 2 diabetes; gastric cancer
|
|
Received: 13 August 2017
|
|
|
|
|
|
|
2017, Vol. 27 
